FIGURE 1.

A 54-year-old man with pulmonary neuroendocrine tumor underwent surgical resection and adjuvant chemotherapy. A follow-up PET/CT scan using ⁶⁸Ga-DOTATATE showed focal uptake in the right axilla (A, axial PET; B, axial CT; C, axial fused; and D, coronal PET), localizing to a nonenlarged lymph node on CT (arrows). DOTATATE PET/CT is an imaging technique frequently used for detecting and characterizing neuroendocrine tumors. DOTATATE is a somatostatin analog that binds with great avidity to somatostatin receptors, allowing highly accurate whole-body imaging of tumors expressing somatostatin receptors.^1,2 DOTATATE uptake secondary to inflammatory processes is a known imaging pitfall, with inflammatory uptake usually seen in the postradiation therapy setting.² Inflammatory uptake is frequently low or very low grade. It is important to recognize that nonspecific, inflammatory uptake can also occur with non-FDG radiotracers including DOTATATE.³ New-onset unilateral and, occasionally, bilateral axillary lymphadenopathy is a commonly reported adverse effect of COVID-19 vaccination.^4–7 Recent published data have demonstrated FDG PET-avid axillary lymphadenopathy subsequent to COVID-19 vaccination,^3,8 and this report demonstrates similar findings with DOTATATE. This potential association needs to be recognized by the radiologist, as it may propose a diagnostic dilemma in the workup of metastatic disease. Awareness of each patient’s vaccination schedule is an important factor when scheduling imaging for cancer screening or metastatic disease workup.